Mirum Pharmaceuticals Completes Acquisition of Bluejay Therapeutics, Expanding Global Leadership in Rare Disease ...
Mirum Pharmaceuticals acquires Bluejay Therapeutics, focusing on brelovitug for chronic hepatitis delta virus (HDV), a severe ...
Mirum Pharmaceuticals has entered a definitive agreement to acquire Bluejay Therapeutics — a deal that, if finalized, would add brelovitug, a phase 3-stage monoclonal antibody for chronic hepatitis ...
Findings showed 100% of participants taking the tobevibart and elebsiran combination achieved an undetectable HDV RNA at week 24 that was sustained through week 60. The Food and Drug Administration ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results